Reviews Estradiol Cypionate Injection


No reviews yet.

Depo-Estradiol Drug Description
DEPO®-ESTRADIOL
(estradiol cypionate) Injection, USP

WARNINGS:
ESTROGENS INCREASE THE RISK OF ENDOMETRIAL CANCER
Close clinical surveillance of all women taking estrogens is important. Adequate
diagnostic measures including endometrial sampling, when indicated, should
be undertaken to rule out malignancy in all cases of undiagnosed persistent
or recurring abnormal vaginal bleeding. There is currently no evidence that
the use of “natural” estrogens results in a different endometrial risk profile
than “synthetic” estrogens at equivalent estrogen doses. (See WARNINGS,
malignant neoplasms, Endometrial cancer.)
CARDIOVASCULAR AND OTHER RISKS
Estrogens with and without progestins should not be used for the prevention
of cardiovascular disease. (See WARNINGS, Cardiovascular
disorders.)
The Women's Health Initiative (WHI) study reported increased risks of myocardial
infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein
thrombosis in postmenopausal women (50 to 79 years of age) during 5 years
of treatment with oral conjugated estrogens (CE 0.625 mg) combined with medroxyprogesterone
acetate (MPA 2.5 mg) relative to placebo. (See CLINICAL PHARMACOLOGY, Clinical
Studies.)
The Women's Health Initiative Memory Study (WHIMS), a substudy of WHI, reported
increased risk of developing probable dementia in postmenopausal women 65
years of age or older during 4 years of treatment with oral conjugated estrogens
plus medroxyprogesterone acetate relative to placebo. It is unknown whether
this finding applies to younger postmenopausal women or to women taking estrogen-alone
therapy. (See CLINICAL PHARMACOLOGY, Clinical Studies.)
Other doses of conjugated estrogens with medroxyprogesterone acetate, and other combinations and dosage forms of estrogens and progestins were not studied in the WHI clinical trials and, in the absence of comparable data, these risks should be assumed to be similar. Because of these risks, estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.

DRUG DESCRIPTION
DEPO-Estradiol Injection contains estradiol cypionate for intramuscular use.
Each mL contains:
5 mg/mL—5 mg estradiol cypionate, 5.4 mg chlorobutanol anhydrous (chloral derivative)
added as preservative; in 913 mg cottonseed oil.
Warning: Chlorobutanol may be habit forming. The structural formula
is represented below:








DEPO-Estradiol contains an oil soluble ester of estradiol 17β. The chemical name for estradiol cypionate is estradiol 17-cyclopentanepropionate.
Last reviewed on RxList: 8/25/2009




Depo-Estradiol Drug Description
DEPO®-ESTRADIOL
(estradiol cypionate) Injection, USP

WARNINGS:
ESTROGENS INCREASE THE RISK OF ENDOMETRIAL CANCER
Close clinical surveillance of all women taking estrogens is important. Adequate
diagnostic measures including endometrial sampling, when indicated, should
be undertaken to rule out malignancy in all cases of undiagnosed persistent
or recurring abnormal vaginal bleeding. There is currently no evidence that
the use of “natural” estrogens results in a different endometrial risk profile
than “synthetic” estrogens at equivalent estrogen doses. (See WARNINGS,
malignant neoplasms, Endometrial cancer.)
CARDIOVASCULAR AND OTHER RISKS
Estrogens with and without progestins should not be used for the prevention
of cardiovascular disease. (See WARNINGS, Cardiovascular
disorders.)
The Women's Health Initiative (WHI) study reported increased risks of myocardial
infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein
thrombosis in postmenopausal women (50 to 79 years of age) during 5 years
of treatment with oral conjugated estrogens (CE 0.625 mg) combined with medroxyprogesterone
acetate (MPA 2.5 mg) relative to placebo. (See CLINICAL PHARMACOLOGY, Clinical
Studies.)
The Women's Health Initiative Memory Study (WHIMS), a substudy of WHI, reported
increased risk of developing probable dementia in postmenopausal women 65
years of age or older during 4 years of treatment with oral conjugated estrogens
plus medroxyprogesterone acetate relative to placebo. It is unknown whether
this finding applies to younger postmenopausal women or to women taking estrogen-alone
therapy. (See CLINICAL PHARMACOLOGY, Clinical Studies.)
Other doses of conjugated estrogens with medroxyprogesterone acetate, and other combinations and dosage forms of estrogens and progestins were not studied in the WHI clinical trials and, in the absence of comparable data, these risks should be assumed to be similar. Because of these risks, estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.

DRUG DESCRIPTION
DEPO-Estradiol Injection contains estradiol cypionate for intramuscular use.
Each mL contains:
5 mg/mL—5 mg estradiol cypionate, 5.4 mg chlorobutanol anhydrous (chloral derivative)
added as preservative; in 913 mg cottonseed oil.
Warning: Chlorobutanol may be habit forming. The structural formula
is represented below:








DEPO-Estradiol contains an oil soluble ester of estradiol 17β. The chemical name for estradiol cypionate is estradiol 17-cyclopentanepropionate.
Last reviewed on RxList: 8/25/2009




Depo-Estradiol Drug Description
DEPO®-ESTRADIOL
(estradiol cypionate) Injection, USP

WARNINGS:
ESTROGENS INCREASE THE RISK OF ENDOMETRIAL CANCER
Close clinical surveillance of all women taking estrogens is important. Adequate
diagnostic measures including endometrial sampling, when indicated, should
be undertaken to rule out malignancy in all cases of undiagnosed persistent
or recurring abnormal vaginal bleeding. There is currently no evidence that
the use of “natural” estrogens results in a different endometrial risk profile
than “synthetic” estrogens at equivalent estrogen doses. (See WARNINGS,
malignant neoplasms, Endometrial cancer.)
CARDIOVASCULAR AND OTHER RISKS
Estrogens with and without progestins should not be used for the prevention
of cardiovascular disease. (See WARNINGS, Cardiovascular
disorders.)
The Women's Health Initiative (WHI) study reported increased risks of myocardial
infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein
thrombosis in postmenopausal women (50 to 79 years of age) during 5 years
of treatment with oral conjugated estrogens (CE 0.625 mg) combined with medroxyprogesterone
acetate (MPA 2.5 mg) relative to placebo. (See CLINICAL PHARMACOLOGY, Clinical
Studies.)
The Women's Health Initiative Memory Study (WHIMS), a substudy of WHI, reported
increased risk of developing probable dementia in postmenopausal women 65
years of age or older during 4 years of treatment with oral conjugated estrogens
plus medroxyprogesterone acetate relative to placebo. It is unknown whether
this finding applies to younger postmenopausal women or to women taking estrogen-alone
therapy. (See CLINICAL PHARMACOLOGY, Clinical Studies.)
Other doses of conjugated estrogens with medroxyprogesterone acetate, and other combinations and dosage forms of estrogens and progestins were not studied in the WHI clinical trials and, in the absence of comparable data, these risks should be assumed to be similar. Because of these risks, estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.

DRUG DESCRIPTION
DEPO-Estradiol Injection contains estradiol cypionate for intramuscular use.
Each mL contains:
5 mg/mL—5 mg estradiol cypionate, 5.4 mg chlorobutanol anhydrous (chloral derivative)
added as preservative; in 913 mg cottonseed oil.
Warning: Chlorobutanol may be habit forming. The structural formula
is represented below:








DEPO-Estradiol contains an oil soluble ester of estradiol 17β. The chemical name for estradiol cypionate is estradiol 17-cyclopentanepropionate.
Last reviewed on RxList: 8/25/2009




Depo-Estradiol Drug Description
DEPO®-ESTRADIOL
(estradiol cypionate) Injection, USP

WARNINGS:
ESTROGENS INCREASE THE RISK OF ENDOMETRIAL CANCER
Close clinical surveillance of all women taking estrogens is important. Adequate
diagnostic measures including endometrial sampling, when indicated, should
be undertaken to rule out malignancy in all cases of undiagnosed persistent
or recurring abnormal vaginal bleeding. There is currently no evidence that
the use of “natural” estrogens results in a different endometrial risk profile
than “synthetic” estrogens at equivalent estrogen doses. (See WARNINGS,
malignant neoplasms, Endometrial cancer.)
CARDIOVASCULAR AND OTHER RISKS
Estrogens with and without progestins should not be used for the prevention
of cardiovascular disease. (See WARNINGS, Cardiovascular
disorders.)
The Women's Health Initiative (WHI) study reported increased risks of myocardial
infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein
thrombosis in postmenopausal women (50 to 79 years of age) during 5 years
of treatment with oral conjugated estrogens (CE 0.625 mg) combined with medroxyprogesterone
acetate (MPA 2.5 mg) relative to placebo. (See CLINICAL PHARMACOLOGY, Clinical
Studies.)
The Women's Health Initiative Memory Study (WHIMS), a substudy of WHI, reported
increased risk of developing probable dementia in postmenopausal women 65
years of age or older during 4 years of treatment with oral conjugated estrogens
plus medroxyprogesterone acetate relative to placebo. It is unknown whether
this finding applies to younger postmenopausal women or to women taking estrogen-alone
therapy. (See CLINICAL PHARMACOLOGY, Clinical Studies.)
Other doses of conjugated estrogens with medroxyprogesterone acetate, and other combinations and dosage forms of estrogens and progestins were not studied in the WHI clinical trials and, in the absence of comparable data, these risks should be assumed to be similar. Because of these risks, estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.

DRUG DESCRIPTION
DEPO-Estradiol Injection contains estradiol cypionate for intramuscular use.
Each mL contains:
5 mg/mL—5 mg estradiol cypionate, 5.4 mg chlorobutanol anhydrous (chloral derivative)
added as preservative; in 913 mg cottonseed oil.
Warning: Chlorobutanol may be habit forming. The structural formula
is represented below:








DEPO-Estradiol contains an oil soluble ester of estradiol 17β. The chemical name for estradiol cypionate is estradiol 17-cyclopentanepropionate.
Last reviewed on RxList: 8/25/2009




Depo-Estradiol Drug Description
DEPO®-ESTRADIOL
(estradiol cypionate) Injection, USP

WARNINGS:
ESTROGENS INCREASE THE RISK OF ENDOMETRIAL CANCER
Close clinical surveillance of all women taking estrogens is important. Adequate
diagnostic measures including endometrial sampling, when indicated, should
be undertaken to rule out malignancy in all cases of undiagnosed persistent
or recurring abnormal vaginal bleeding. There is currently no evidence that
the use of “natural” estrogens results in a different endometrial risk profile
than “synthetic” estrogens at equivalent estrogen doses. (See WARNINGS,
malignant neoplasms, Endometrial cancer.)
CARDIOVASCULAR AND OTHER RISKS
Estrogens with and without progestins should not be used for the prevention
of cardiovascular disease. (See WARNINGS, Cardiovascular
disorders.)
The Women's Health Initiative (WHI) study reported increased risks of myocardial
infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein
thrombosis in postmenopausal women (50 to 79 years of age) during 5 years
of treatment with oral conjugated estrogens (CE 0.625 mg) combined with medroxyprogesterone
acetate (MPA 2.5 mg) relative to placebo. (See CLINICAL PHARMACOLOGY, Clinical
Studies.)
The Women's Health Initiative Memory Study (WHIMS), a substudy of WHI, reported
increased risk of developing probable dementia in postmenopausal women 65
years of age or older during 4 years of treatment with oral conjugated estrogens
plus medroxyprogesterone acetate relative to placebo. It is unknown whether
this finding applies to younger postmenopausal women or to women taking estrogen-alone
therapy. (See CLINICAL PHARMACOLOGY, Clinical Studies.)
Other doses of conjugated estrogens with medroxyprogesterone acetate, and other combinations and dosage forms of estrogens and progestins were not studied in the WHI clinical trials and, in the absence of comparable data, these risks should be assumed to be similar. Because of these risks, estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.

DRUG DESCRIPTION
DEPO-Estradiol Injection contains estradiol cypionate for intramuscular use.
Each mL contains:
5 mg/mL—5 mg estradiol cypionate, 5.4 mg chlorobutanol anhydrous (chloral derivative)
added as preservative; in 913 mg cottonseed oil.
Warning: Chlorobutanol may be habit forming. The structural formula
is represented below:








DEPO-Estradiol contains an oil soluble ester of estradiol 17β. The chemical name for estradiol cypionate is estradiol 17-cyclopentanepropionate.
Last reviewed on RxList: 8/25/2009





Other reviews about Estradiol Cypionate Injection on wordpress

male-sex-hormone-testosterone
  by Dr. Ashok Koparday
Is SHE depressed? Is her sex drive reduced?Does HE have nervousness, depression, impaired memory, inability to concentrate, fatigue, insomnia, hot flushes, sweating, decreased libido? It could be because […]


Testosterone
  by EdR
-A Critical Hormone for Men and Womenby Jeffry S. Life, M.D. Ph.D.Men and TestosteroneTestosterone is a hormone that has been intimately tied throughout time to a man’s virility […]


HRT MISINFORMATION CORRECTED BY INTERNATIONAL AUTHORITIES.
  by healthspanlife
The new study from the Women's Health Initiative WHI -Ness 2009 : Influence of Estrogen Plus Testosterone Supplementation on Breast Cancer misreports/ conceals the truth:  contrary to it’s […]


ANABOLIZING THE FAINT-HEARTED WITH PHYSIOLOGICAL TESTOSTERONE REPLACEMENT
  by healthspanlife
Some 2600 years after the first recorded therapeutic use of  human hormone replacement (in China), and about a century after the first modern hormone use, two new landmark […]


James Ray's Sedona sweat lodge stash: lessons in polypharmacy and endocrine pharmacology
  by David
On October 8, 2009, paramedics responded to a 911 call at a mystical retreat being held at Angel Valley Spiritual Retreat Center in West Sedona, Arizona, a stunningly […]


The CFIA must put an immediate end to horse slaughter
  by Vivian
The Canadian Food Inspection Agency (CFIA) have as part of their Equine Identification Document (EID) a list of drugs that are permitted and not permitted for use on […]


Carrie went out the back door, staggered
  by awdnxkhvcwnr
He had been out since early dawn at the sealholes, eight miles away, and had come home with three big seal. It had been arranged in the morning […]


The lanky one smiled in embarras
  by oqfjeldlxw
I am afraid we have exhausted you. I was seized by the consequent panic, and went over the side in a surge of bodies. The three set […]



Other reviews about Estradiol Cypionate Injection on web:

Consumer information about the medication ESTRADIOL CYPIONATE INJECTION (Dep-Gynogen, Depo-Estradiol, Depogen), includes side effects, drug interactions, recommended dosages ... ESTRADIOL CYPIONATE INJECTION (Dep-Gynogen, Depo-Estradiol ...


Estradiol Cypionate; Medroxyprogesterone contraceptive injection To return to the main entry click here Estradiol Cypionate; Medroxyprogesterone contraceptive injection ...


DEPO ®-ESTRADIOL Estradiol cypionate injection, USP WARNINGS: ESTROGENS INCREASE THE RISK OF ENDOMETRIAL CANCER Close clinical surveillance of all women taking estrogens is ... DEPO®-ESTRADIOL Estradiol cypionate injection, USP


Estradiol injection To return to the main entry click here . What are estradiol injections? ESTRADIOL CYPIONATE (DepGynogen®, Estradiol injection: Information from Answers.com


DEPO ®-Estradiol Estradiol cypionate injection, USP DEPO-Estradiol Injection (estradiol cypionate USP) is an estrogen product for injection. The information below is that ... DEPO®-Estradiol Estradiol cypionate injection, USP


Learn about the prescription medication Depo-Estradiol (Estradiol Cypionate Injection), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient labeling. Depo-Estradiol (Estradiol Cypionate Injection) Drug Information ...


Estradiol Cypionate is usually given as an injection at your doctor's office, hospital, or clinic. If you will be using Estradiol Cypionate at home, a health care provider will ... Estradiol Cypionate Facts and Comparisons at Drugs.com


In the case of bitches, the prolonged action of estradiol cypionate may, in some instances, interfere with nidation. When used in mismated bitches, injection should be made as soon ... Estradiol Cypionate in Oil (Canada) Veterinary Information from ...


Medroxyprogesterone-Estradiol Cypionate Injection: In 1995, more than 44 million women in the United States between 15 and 44 years of age had used the pill at least once, and ... New Hormonal Contraceptives: Medroxyprogesterone-Estradiol ...


Information on the Pfizer product DEPO-ESTRADIOL. ... DEPO-ESTRADIOL ® (estradiol cypionate injection, USP) This product information is intended only for residents of the ... DEPO-ESTRADIOL | Pfizer: the world's largest research-based ...





Featured Reviews

Reviews Claritin D

Claritin D Drug Description Claritin D (loratadine and pseudoephedrine) 12 hour and 24 hour Extended Release Tablets Now available Over-the-Counter DRUG DESCRIPTION What are the possible side effects of desloratadine and pseudoephedrine...
Read More  |  Review This
Reviews Renvela

Renvela Drug Description Renvela® (sevelamer carbonate) Tablets Renvela® (sevelamer carbonate) For Oral Suspension DRUG DESCRIPTION What are the possible side effects of sevelamer (Renagel, Renvela)? Get emergency medical...
Read More  |  Review This
Reviews Pediotic

Pediotic Drug Description PEDIOTIC® Suspension Sterile (neomycin and polymyxin B sulfates and hydrocortisone) Otic Suspension, USP DRUG DESCRIPTION PEDIOTIC® Suspension (neomycin and polymyxin B sulfates and hydrocortisone ...
Read More  |  Review This
Reviews Zoledronic Acid Injection

Reclast Drug Description Reclast® (zoledronic acid) Injection DRUG DESCRIPTION What are the possible side effects of zoledronic acid (Reclast, Zometa)? Get emergency medical help if you have any of these signs of an allergic...
Read More  |  Review This
Reviews Synagis

Synagis Drug Description SYNAGIS® (palivizumab) DRUG DESCRIPTION What are the possible side effects of palivizumab (Synagis)? Get emergency medical help if your child has any of these signs of an allergic reaction: hives;...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....